PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats

Annemarie Brüel, Jens Bay Vegger, Anders Christer Raffalt, Jens Enevold Thaulov Andersen, Jesper Skovhus Thomsen

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

PTH and strontium ranelate (SrR) have both been shown to reduce bone loss induced by immobilization. PTH is a potent bone anabolic agent, whereas SrR has been suggested to be an antiresorptive as well as a bone anabolic agent.The aim of the study was to investigate whether PTH, SrR, and PTH and SrR in combination could counteract immobilization-induced bone loss in a rat model.Immobilization was induced by injecting 4. IU Botox (BTX) into the muscles of the right hind limb. Seventy-two female Wistar rats, 3-months-old, were divided into the following groups: Baseline, Controls, BTX, BTX + PTH, BTX + SrR, and BTX + PTH + SrR (n = 12 in each group). PTH was given as injections (SC) at a dosage of 60 μg/kg/d, and SrR as 900. mg/kg/d in the diet. The experiment lasted for 4. weeks.BTX resulted in lower trabecular bone formation rate (-68%) and periosteal bone formation rate (-91%), and a higher fraction of osteoclast-covered surfaces (+ 53%) compared with controls. This was accompanied by significantly lower trabecular bone volume fraction (-24%), trabecular thickness (-16%), and bone strength (-14% to -32% depending on site). PTH alone counteracted immobilization-induced losses in trabecular (4-fold increase vs. BTX) and periosteal (5-fold increase vs. BTX) bone formation rate, trabecular thickness (+ 25% vs. BTX) and femoral neck strength (+ 24% vs. BTX). In contrast, SrR did not influence BTX-induced loss of bone formation rate, trabecular bone volume fraction, trabecular thickness, or bone strength. Finally, no additive effect was found when PTH and SrR treatments were combined.In conclusion, PTH counteracted loss in bone architecture and bone strength in immobilized rats, whereas as no effect of SrR was found. Moreover, no additional effect was found by combining PTH with SrR.

Original languageEnglish
Pages (from-to)51-58
Number of pages8
JournalBone
Volume53
Issue number1
DOIs
Publication statusPublished - Mar 1 2013

Fingerprint

strontium ranelate
Parathyroid Hormone
Bone and Bones
Osteogenesis
Immobilization
Anabolic Agents
Cancellous Bone
onabotulinumtoxinA

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Cite this

Brüel, Annemarie ; Vegger, Jens Bay ; Raffalt, Anders Christer ; Andersen, Jens Enevold Thaulov ; Thomsen, Jesper Skovhus. / PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats. In: Bone. 2013 ; Vol. 53, No. 1. pp. 51-58.
@article{9d562811221349d1a89afc777bb8ff4a,
title = "PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats",
abstract = "PTH and strontium ranelate (SrR) have both been shown to reduce bone loss induced by immobilization. PTH is a potent bone anabolic agent, whereas SrR has been suggested to be an antiresorptive as well as a bone anabolic agent.The aim of the study was to investigate whether PTH, SrR, and PTH and SrR in combination could counteract immobilization-induced bone loss in a rat model.Immobilization was induced by injecting 4. IU Botox (BTX) into the muscles of the right hind limb. Seventy-two female Wistar rats, 3-months-old, were divided into the following groups: Baseline, Controls, BTX, BTX + PTH, BTX + SrR, and BTX + PTH + SrR (n = 12 in each group). PTH was given as injections (SC) at a dosage of 60 μg/kg/d, and SrR as 900. mg/kg/d in the diet. The experiment lasted for 4. weeks.BTX resulted in lower trabecular bone formation rate (-68{\%}) and periosteal bone formation rate (-91{\%}), and a higher fraction of osteoclast-covered surfaces (+ 53{\%}) compared with controls. This was accompanied by significantly lower trabecular bone volume fraction (-24{\%}), trabecular thickness (-16{\%}), and bone strength (-14{\%} to -32{\%} depending on site). PTH alone counteracted immobilization-induced losses in trabecular (4-fold increase vs. BTX) and periosteal (5-fold increase vs. BTX) bone formation rate, trabecular thickness (+ 25{\%} vs. BTX) and femoral neck strength (+ 24{\%} vs. BTX). In contrast, SrR did not influence BTX-induced loss of bone formation rate, trabecular bone volume fraction, trabecular thickness, or bone strength. Finally, no additive effect was found when PTH and SrR treatments were combined.In conclusion, PTH counteracted loss in bone architecture and bone strength in immobilized rats, whereas as no effect of SrR was found. Moreover, no additional effect was found by combining PTH with SrR.",
author = "Annemarie Br{\"u}el and Vegger, {Jens Bay} and Raffalt, {Anders Christer} and Andersen, {Jens Enevold Thaulov} and Thomsen, {Jesper Skovhus}",
year = "2013",
month = "3",
day = "1",
doi = "10.1016/j.bone.2012.11.037",
language = "English",
volume = "53",
pages = "51--58",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "1",

}

PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats. / Brüel, Annemarie; Vegger, Jens Bay; Raffalt, Anders Christer; Andersen, Jens Enevold Thaulov; Thomsen, Jesper Skovhus.

In: Bone, Vol. 53, No. 1, 01.03.2013, p. 51-58.

Research output: Contribution to journalArticle

TY - JOUR

T1 - PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats

AU - Brüel, Annemarie

AU - Vegger, Jens Bay

AU - Raffalt, Anders Christer

AU - Andersen, Jens Enevold Thaulov

AU - Thomsen, Jesper Skovhus

PY - 2013/3/1

Y1 - 2013/3/1

N2 - PTH and strontium ranelate (SrR) have both been shown to reduce bone loss induced by immobilization. PTH is a potent bone anabolic agent, whereas SrR has been suggested to be an antiresorptive as well as a bone anabolic agent.The aim of the study was to investigate whether PTH, SrR, and PTH and SrR in combination could counteract immobilization-induced bone loss in a rat model.Immobilization was induced by injecting 4. IU Botox (BTX) into the muscles of the right hind limb. Seventy-two female Wistar rats, 3-months-old, were divided into the following groups: Baseline, Controls, BTX, BTX + PTH, BTX + SrR, and BTX + PTH + SrR (n = 12 in each group). PTH was given as injections (SC) at a dosage of 60 μg/kg/d, and SrR as 900. mg/kg/d in the diet. The experiment lasted for 4. weeks.BTX resulted in lower trabecular bone formation rate (-68%) and periosteal bone formation rate (-91%), and a higher fraction of osteoclast-covered surfaces (+ 53%) compared with controls. This was accompanied by significantly lower trabecular bone volume fraction (-24%), trabecular thickness (-16%), and bone strength (-14% to -32% depending on site). PTH alone counteracted immobilization-induced losses in trabecular (4-fold increase vs. BTX) and periosteal (5-fold increase vs. BTX) bone formation rate, trabecular thickness (+ 25% vs. BTX) and femoral neck strength (+ 24% vs. BTX). In contrast, SrR did not influence BTX-induced loss of bone formation rate, trabecular bone volume fraction, trabecular thickness, or bone strength. Finally, no additive effect was found when PTH and SrR treatments were combined.In conclusion, PTH counteracted loss in bone architecture and bone strength in immobilized rats, whereas as no effect of SrR was found. Moreover, no additional effect was found by combining PTH with SrR.

AB - PTH and strontium ranelate (SrR) have both been shown to reduce bone loss induced by immobilization. PTH is a potent bone anabolic agent, whereas SrR has been suggested to be an antiresorptive as well as a bone anabolic agent.The aim of the study was to investigate whether PTH, SrR, and PTH and SrR in combination could counteract immobilization-induced bone loss in a rat model.Immobilization was induced by injecting 4. IU Botox (BTX) into the muscles of the right hind limb. Seventy-two female Wistar rats, 3-months-old, were divided into the following groups: Baseline, Controls, BTX, BTX + PTH, BTX + SrR, and BTX + PTH + SrR (n = 12 in each group). PTH was given as injections (SC) at a dosage of 60 μg/kg/d, and SrR as 900. mg/kg/d in the diet. The experiment lasted for 4. weeks.BTX resulted in lower trabecular bone formation rate (-68%) and periosteal bone formation rate (-91%), and a higher fraction of osteoclast-covered surfaces (+ 53%) compared with controls. This was accompanied by significantly lower trabecular bone volume fraction (-24%), trabecular thickness (-16%), and bone strength (-14% to -32% depending on site). PTH alone counteracted immobilization-induced losses in trabecular (4-fold increase vs. BTX) and periosteal (5-fold increase vs. BTX) bone formation rate, trabecular thickness (+ 25% vs. BTX) and femoral neck strength (+ 24% vs. BTX). In contrast, SrR did not influence BTX-induced loss of bone formation rate, trabecular bone volume fraction, trabecular thickness, or bone strength. Finally, no additive effect was found when PTH and SrR treatments were combined.In conclusion, PTH counteracted loss in bone architecture and bone strength in immobilized rats, whereas as no effect of SrR was found. Moreover, no additional effect was found by combining PTH with SrR.

UR - http://www.scopus.com/inward/record.url?scp=84871503533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871503533&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2012.11.037

DO - 10.1016/j.bone.2012.11.037

M3 - Article

C2 - 23246791

AN - SCOPUS:84871503533

VL - 53

SP - 51

EP - 58

JO - Bone

JF - Bone

SN - 8756-3282

IS - 1

ER -